Patents by Inventor Ching Sieu Tay

Ching Sieu Tay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORMS
    Publication number: 20240108582
    Abstract: A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.
    Type: Application
    Filed: September 11, 2023
    Publication date: April 4, 2024
    Applicant: Evecxia Therapeutics, Inc.
    Inventors: Jacob Pade Ramsoe Jacobsen, Bret Berner, Wu Lin, Ching Sieu Tay
  • 5-hydroxytryptophan gastroretentive dosage forms
    Patent number: 11752107
    Abstract: A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: September 12, 2023
    Assignee: Evecxia Therapeutics, Inc.
    Inventors: Jacob Pade Ramsoe Jacobsen, Bret Berner, Wu Lin, Ching Sieu Tay
  • 5-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORMS
    Publication number: 20230047338
    Abstract: A gastroretentive, sustained-release dosage form including 5-hydroxytryptophan (5-HTP) as an active ingredient and low-dose carbidopa is described. For example, the dosage form can be provided as a bilayer tablet comprising a swelling layer and a modified release layer, where the 5-HTP and carbidopa are both included in the modified release layer. The dosage form provides for essentially parallel release of the 5-HTP and the carbidopa with, for instance, release of 80% of the 5-HTP and carbidopa at about 5 hours to about 12 hours.
    Type: Application
    Filed: July 29, 2022
    Publication date: February 16, 2023
    Inventors: Jacob Pade Ramsoe Jacobsen, Bret Berner, Wu Lin, Ching Sieu Tay